

IBC Meeting Minutes

Cleveland Clinic Florida Research and Innovation Center

Date: June 18 th , 2026	Location: Zoom
IBC Member Attendance: ☒ McDonald, Christine (IBC Chair) ☐ Li, Kun ☒ Such, Kimberly ☐ Champer, Dylan (Biosafety Officer) ☒ Hajjar, Adeline ☐ Judd, Leslie ☒ Dragan, Amanda (Acting Biosafety Officer) ☐ O'Connor, Christine ☒ Doud, Melissa ☒ Tavakoli, Sara ☒ Stolley, Michael <i>Guests: Anna Rietsch *, Anthony Santilli*, Jennifer Veillette*, Nikki Meyer*, Abby Bifano</i> <i>*Cleveland Clinic Main Campus</i>	
Call To Order: 2:30 pm	Adjourn: 2:52 pm

I. Review of May 21st, 2026 Meeting Minutes

Committee Comments: None			
Motion: Approved	For: 6	Against: 0	Abstain: 1

II. Administrative Business

- a. Committee presented with Subcommittee Review items, personnel additions, and updates to programmatic SOPs.
- b. Incident Report: IBC Members were informed of an incident involving a near miss in the BSL-3. The resulting risk assessments and corrective actions taken to prevent further occurrences were also presented.
- c. Incident Report: IBC Members were informed of a PPE failure in the BSL-3. The resulting risk assessments and corrective actions taken to prevent further occurrences were also presented.
- d. Incident Report: IBC Members were informed of an individual with a recent entry reporting symptoms to Occupational Health. Occupational Health determined that no exposure had occurred.
- e. Lab Audits: Members were presented with and informed of Preliminary Audits occurring during the month of June 2026. No major deficiencies were identified.

III. Non-Clinical Research:

a. Renewals:

Basic Research Renewal # 1	Protocol ID: FLIBC020	PI: Thomas	Biosafety Level: BSL-3	NIH Cat.: N/A	
Project Titles: Sample preparation, cell sorting and flow-cytometric analysis of unfixed samples requiring BSL-3 containment.					
Associated Grant Numbers: Non-NIH Funding					
Protocol Summary: Sample preparation, cell sorting and flow cytometric analysis of fixed and unfixed samples containing Risk Group 3 agents. All agent has to be approved by the IBC for each investigator, before use on Core equipment; Human derived materials. <u>Function/Nature of Recombinant Genes to be Expressed:</u> ☐ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☒ Other <u>Species of Recombinant Genes to be Expressed:</u> ☐ N/A ☐ Human ☐ Murine ☐ Rat ☐ Bacterial ☒ Viral ☒ Other					
Risk Assessment Discussion: ☒ Yes ☐ No		Facilities, Procedures, and Safety Practices Reviewed (Y/N): ☒ Yes ☐ No			
Discussion/Required Modifications: Administrative edits					
PI/Supervisor Training (Y/N): ☒ Yes ☐ No		Handler Training (Y/N): ☒ Yes ☐ No			
Motion: Approved with Administrative Revisions	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0